<h4>Objective</h4>Breast cancer survivors undergoing hormonal therapy with aromatase inhibitors face a significantly increased risk of developing musculoskeletal pain, leading to treatment discontinuation rates of 13% to 22%. Here, CYP19A1 is linked to breast carcinoma.